A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-27. Anything still debated is marked as such rather than presented as settled.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
On October 31, 2024, the European Commission fined Teva €462.6 million "over misuse of the patent system and disparagement to delay [a] rival multiple sclerosis medicine", namely Copaxone (glatiramer acetate). Teva is accused of having attempted to obstacle other producers of glatiramer acetate both by abusing the patent system and by setting up a misinformation campaign targeting other glatiramer producers.
Significant linkage was also detected in the pericentromeric region of chromosome 8, overlapping with one of the regions detected in the Hamer lab's previous genomewide study. The authors concluded, "Results, especially in the context of past studies, support the existence of genes on pericentromeric chromosome 8 and chromosome Xq28 influencing development of male sexual orientation." In 2019, a genome-wide association study of 493,001 individuals concluded that hundreds or thousands of genetic variants underlie same-sex sexual behavior in both sexes, but in contrast to linkage studies they found no excess of signal on Xq28 or the rest of the X chromosome. This study was questioned on account of its reliance on a dichotomous ever/never measure that lumped together predominantly heterosexual, bisexual and homosexual individuals, including those who only experimented once with a same-sex partner, possibly resulting in misleading associations to personality traits. Hamer said that the findings of the 2019 study do not reveal any biological pathways for sexual orientation, but stated he hoped it would be the first of many to come. Hamer's findings provoked extensive public reaction, often based on misunderstanding of the science, which led to his interest in explaining the data to a wide audience through a book written in collaboration with a journalist. A 2016 article "Sexual Orientation, Controversy, and Science" includes a review of molecular genetics studies related to sexuality, starting with Hamer's work.
== Early life and education == Schumer was born on June 1, 1981, on the Upper East Side of Manhattan, New York City, to Sandra Jane (née Jones, or Johns) and Gordon David Schumer, who owned a baby furniture company. Schumer's father was born to a Jewish family from Ukraine. She is a second cousin, once removed, of U.S. Senator and Senate Minority Leader Chuck Schumer. Her mother is from a Protestant background and has deep New England roots, and converted to Judaism before her marriage. Schumer was raised Jewish and says she had to deal with antisemitism as a child, but is not observant as an adult. Her mother is of Puritan ancestry dating back to the colonial-era Massachusetts Bay Colony. In 2017, as a guest on Finding Your Roots, Schumer learned that in 1704, three children from her ancestor Thomas Tarbell's family were captured at Groton, Massachusetts, in a French-Abenaki raid and taken to Montreal. The girl was ransomed by a French-Canadian family and ultimately joined a French Catholic convent; the two boys were each adopted by Mohawk families at Kahnawake and became thoroughly assimilated. They married Mohawk women and some of their descendants became chiefs. There are still Mohawk by the surname Tarbell in Kahnawake and Akwesasne, another village reserve on the St. Lawrence River founded by the brothers. Through the success of her father's furniture company in Manhattan, Schumer's household was wealthy during her early years. When she was nine years old her father's business failed and he went bankrupt. He was subsequently diagnosed with multiple sclerosis.
Sources: en.wikipedia.org
Additionally, it reacts with NADPH-dependent acetoacetyl-coenzyme A reductase, also known as PhaB, in a pathway that produces polyester polyhydroxyalkanoate (PHA). The reduction of acetoacetyl-coA by Pha creates (R)-3-hydroxybutyryl-CoA, which polymerizes to PHA. The pathway is present in bacteria such as Ralstonia eutropha and the PCC6803 strain of Synechocystis. Mover over, Acetoacetyl-CoA is involved with neuronal development involving lipogenesis and providing fats and cholesterol for neuronal cells.
==== 2000–2099 ==== Value Added Tax (Payments on Account) Order 1993 (S.I. 1993/2001) Friendly Societies Appeal Tribunal Regulations 1993 (S.I. 1993/2002) Income Tax (Stock Lending) (Amendment) Regulations 1993 (S.I. 1993/2003) Income Tax (Manufactured Overseas Dividends) Regulations 1993 (S.I. 1993/2004) Cereal Seeds Regulations 1993 (S.I. 1993/2005) Beet Seeds Regulations 1993 (S.I. 1993/2006) Oil and Fibre Plant Seeds Regulations 1993 (S.I. 1993/2007) Vegetable Seeds Regulations 1993 (S.I. 1993/2008) Fodder Plant Seeds Regulations 1993 (S.I. 1993/2009) Tuberculosis (Deer) (Amendment) Order 1993 (S.I. 1993/2010) Local Government Superannuation (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/2013) Local Authorities (Capital Finance) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2014) Fishing Boats (Marking and Documentation) (Enforcement) Order 1993 (S.I. 1993/2015) Sea Fishing (Enforcement of Community Control Measures) Order 1993 (S.I. 1993/2016) Food Premises (Registration) Amendment Regulations 1993 (S.I. 1993/2022) Criminal Justice Act 1993 (Commencement No. 2 Transitional Provisions and Savings) (Scotland) Order 1993 (S.I. 1993/2035) Public Trusts (Reorganisation) (Scotland) Regulations 1993 (S.I. 1993/2036) Agricultural Holdings (Units of Production) Order 1993 (S.I. 1993/2037) Agriculture Act 1993 (Commencement No. 1) Order 1993 (S.I. 1993/2038) Agriculture Act 1993 (Specification of Year) (Potato Target Area) Order 1993 (S.I. 1993/2039) International Development Association (Tenth Replenishment) Order 1993 (S.I.
In contrast to the elemental ions sodium, potassium, and calcium, there is no known cellular mechanism specifically dedicated to regulating intracellular lithium. Lithium can enter cells through epithelial sodium channels. Lithium ions interfere with ion transport processes (see "Sodium pump") that relay and amplify messages carried to the cells of the brain. Mania is associated with irregular increases in protein kinase C (PKC) activity within the brain. Lithium carbonate and sodium valproate, another drug conventionally used to treat the disorder, act in the brain by inhibiting PKC's activity and help to produce other compounds that also inhibit the PKC. Lithium carbonate's mood-controlling properties are not fully understood.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.